ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

VRAX Virax Biolabs Group Ltd

0,61
-0,039 (-6,01%)
Nach Börsenschluss
Zuletzt aktualisiert: 23:14:22
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Virax Biolabs Group Ltd VRAX NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
-0,039 -6,01% 0,61 23:14:22
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
0,66 0,61 0,6681 0,61 0,649
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
25.4.202414:00PRNUSVirax Biolabs Launches Portfolio of Immune Profiling..
16.4.202413:30PRNUSVirax Biolabs to Participate at ESCMID Global 2024
15.3.202421:30PRNUSVirax Biolabs Announces Receipt of NASDAQ Notification..
22.1.202423:28EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22.1.202423:27EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
12.1.202413:43EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21.12.202313:34EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21.12.202313:30PRNUSVirax Biolabs Forges Strategic Research Collaboration with..
20.12.202322:12EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
20.12.202322:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20.12.202322:03EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
18.12.202313:37EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18.12.202313:30PRNUSVirax Biolabs' CEO James Foster Issues Letter to..
18.12.202306:15EDGAR2Form EFFECT - Notice of Effectiveness
14.12.202313:43EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14.12.202313:30PRNUSVirax Biolabs Group Limited Announces 1-for-10 Share..
08.12.202312:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05.12.202322:06EDGAR2Form F-3 - Registration statement by foreign private issuers
08.11.202322:11EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31.10.202321:38EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12.10.202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04.10.202313:24EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12.9.202313:49EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12.9.202313:30PRNUSVirax Biolabs Group Announces Early-Access Program Launch of..
01.9.202313:37EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01.9.202313:30PRNUSVirax Biolabs Group Appoints Dr. Nigel McCracken as Chief..
03.8.202314:39EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03.8.202313:30PRNUSNasdaq Approves 180-Day Extension for Virax Biolabs Group to..
18.7.202313:58EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18.7.202313:30PRNUSVirax Biolabs Group Continues Growth and Expansion with the..
14.6.202313:30PRNUSVirax Biolabs' CEO James Foster Issues Letter to..
04.5.202313:30PRNUSVirax Biolabs Group Announces Establishment of Regional..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock